Advanced Techniques in Biology & Medicine
Open Access
ISSN: 2379-1764
+44 1223 790975
ISSN: 2379-1764
+44 1223 790975
Department of National Laboratories Capacity Building, Ethiopian Public Health Institute, Addis Ababa, Ethiopia
Research
Genetic Variants among Malaria-Suspected Patients with Glucose-6 Phosphate Dehydrogenase Deficiency
Author(s): Meshesha T Negash*, Lemu Golassa, Sisay Dugassa, Sindew Mekasha Feleke, Desalegn Nega, Abnet Abebe, Boja Dufera, Bacha Mekonen, Geremew Tassew, Bokretsion Gidey, Daniel Kepple, Logan Witherspoon, Eugenia Lo, Tassew Tefera Shenkutie, Aderaw Adamu, Hiwot Amare Hailu, Sileshi Degu and Enirsie Kassie
Background: In Ethiopia, an estimated 68 million people are at risk of malaria–60% caused by Plasmodium falciparum and 40% by Plasmodium vivax. The national elimination program has begun since 2016 with a vision of malaria-free country by 2030. The radical cure of P. Vivax with the drug primaquine is an important component of the elimination strategy. However, Primaquine causes acute hemolytic anemia in glucose-6 phosphate dehydrogenase enzyme deficient patients and is a threat to P. vivax elimination. G6PD is a cytoplasmic enzyme for all human cells that is involved in the pentose phosphate pathway of metabolic reaction and protects red blood cells from cellular oxidative damage by detoxifying free radicals. This study is therefore carried out to determine the G6PD deficiency prevalence among malaria-suspected patients in the.. View More»
DOI:
10.35248/2379-1764.22.10.390